As FGF21 treatment in animal obesity models resulted in reduction of adiposity, improved insulin sensitivity, a decrease of cholesterol and triglyceride levels, FGF21 was suggested to have potential as a novel therapy for obesity and related diseases like T2D and PCOS. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.